Amarin Corp Plcuk (AMRN) Share-based Compensation (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Share-based Compensation of $2.3 million for Q1 2026, down 46.13% YoY from $4.3 million in Q1 2025, and up 44.33% sequentially from $1.6 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Share-based Compensation (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Share-based Compensation across 17 years of filings, most recently posting $2.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 46.13% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $11.9 million (down 28.98% YoY), while the FY2025 annual figure was $13.9 million, down 21.28% from the prior year.
- Share-based Compensation grew to $2.3 million in Q1 2026, from $1.6 million in the prior quarter.
- Over the last five years, Share-based Compensation for AMRN reached as high as $8.6 million in Q2 2022 and fell as low as $1.6 million in Q4 2025.
- The 5-year median for Share-based Compensation is $4.6 million (2023), against an average of $4.5 million.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 248.77% — and 2023, when it sank 78.78%.
- A 5-year view of Share-based Compensation shows it stood at $6.6 million in 2022, then declined by 29.72% to $4.6 million in 2023, then dropped by 26.79% to $3.4 million in 2024, then plunged by 52.53% to $1.6 million in 2025, then surged by 44.33% to $2.3 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.3 million, $1.6 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 161.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 300.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 444.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 185.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 218.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 272.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 2.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.33 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | 4.33 Mn |
| Mar 31, 2025 | 4.33 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Dec 31, 2023 | 4.65 Mn |
| Dec 31, 2023 | 4.65 Mn |